Mixed connective tissue disease

Current Opinion in Rheumatology

Volumn 12, Issue 5, 2000, Pages 386-390

  Hoffman, Robert W ^a   Greidinger, Eric L ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; PEPTIDE DERIVATIVE; RIBONUCLEOPROTEIN; TISSUE POLYPEPTIDE ANTIGEN;

CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; MIXED CONNECTIVE TISSUE DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; AUTOANTIBODIES; HUMANS; HYPERTENSION, PULMONARY; MIXED CONNECTIVE TISSUE DISEASE; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; T-LYMPHOCYTES;

EID: 0033839871     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200009000-00006     Document Type: Review

References (32)

1. Mixed connective tissue disease: To be or not to be?
2. Long-term outcome in mixed connective tissue disease
3. Immunological analysis of pulmonary hypertension in connective tissue diseases
4. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series
5. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin)
6. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein
7. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex
8. Antiphospholipid antibodies among anti-U1 70kD autoantibody-positive mixed connective tissue disease patients
9. Most anticardiolipin antibodies in mixed connective tissue disease are β-glycoprotein independent
10. Autoantibodies to the extracellular matric microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases
11. Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay
12. Autoreactive T cells in murine lupus: Origins and roles in autoantibody production
13. Influence of antigen organization on the development of lupus autoantibodies
14. A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice
15. Genetic susceptibility to systemic lupus erythematosus
16. Control of separate pathogenic autoantibody responses marks MHC gene contributions to murine lupus
17. Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome
18. Clinical usefulness of antibodies to U1 snRNP in mixed connective tissue disease and systemic lupus erythematosus
19. The importance of the light chain for the epitope specificity of human anti-U1 small nuclear RNA autoantibodies present in systemic lupus erythematosus patients
20. Key residues revealed in a major conformational epitope of the U1-70K protein
21. Altered expression level of a systemic nuclear autoantigen determines the fate of immune response to self
22. Analysis of T ceil receptors specific for U1-70kD small nuclear ribonucleoprotein autoantigen: The alpha chain complementarity determining region three is highly conserved among connective tissue disease patients
23. Ultraviolet light-induced keratinocyte apoptosis: A potential mechanism for the induction of skin lesions and autoantibody production in LE
24. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens
25. Association of phosphorylated serine/arginine (SR) splicing factors with the U1-small ribonucleoprotein autoantigen complex accompanies apoptotic cell death
26. Scleroderma autoantigens are uniquely fragmented by metal catalyzed oxidation reactions: Implications for pathogenesis
27. Autoantibody recognition of distinctly modified forms of the U1-70kDa antigen is associated with different clinical disease manifestations
28. Recombinant cytomegalovirus glycoprotein gB (UL55) induces an autoantibody response to the U1-70 kDa small nuclear ribonucleoprotein
29. Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus
30. Side-chain specificities and molecular modelling of peptide determinants for two anti-Sm B/B' autoantibodies
31. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus
32. Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers